Key result
In the Taiwan ACS Full Spectrum Registry of 3,183 patients, 1-year mortality was 6.1% for STEMI, 10.1% for NSTEMI, and 6.2% for unstable angina, with diabetes, CKD, and bleeding predicting worse outcomes.
These registry data should not change practice; leaves open need for prospective validation of predictors in Asian ACS populations.
-VASc score. For high-risk patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), percutaneous coronary intervention (PCI) within 24-72 hours from symptom onset was demonstrably the optimal time. Suboptimal secondary preventive therapy demonstrated a need for further improvement. The ACS Full Spectrum Registry provided an in-depth analysis of ACS management in Taiwan.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2017) conducted a review in Acute Coronary Syndrome (n=3,183). Guideline-directed medical therapy and revascularization was evaluated on 1-year mortality and major adverse cardiac events (MACE). In the Taiwan ACS Full Spectrum Registry of 3,183 patients, 1-year mortality was 6.1% for STEMI, 10.1% for NSTEMI, and 6.2% for unstable angina, with diabetes, CKD, and bleeding predicting worse outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: